Roberts M Scot 4

4 · Altimmune, Inc. · Filed Feb 27, 2026

AI-generated summary of this filing

Updated Feb 27, 2026

Altimmune (ALT) CSO Scot Roberts Receives Equity Award

What Happened

Scot M. Roberts, Chief Scientific Officer of Altimmune, was granted two equity awards on 2026-02-26: 222,670 derivative shares (option award) and 95,430 restricted stock units (RSUs). Both awards were reported at an acquisition price of $0.00, meaning they were grants/awards rather than open‑market purchases or sales. Total granted: 318,100 shares, all subject to vesting schedules.

Key Details

Transaction date: 2026-02-26; Form 4 filed 2026-02-27 (timely).
Awards and reported prices: 222,670 derivative shares @ $0.00; 95,430 RSUs @ $0.00.
Total awarded: 318,100 shares (222,670 options-like awards + 95,430 RSUs).
Shares owned after transaction: Not specified on the Form 4.
Footnotes of note:
- F1: The derivative/option award vests over four years: 25% vest on Feb 26, 2027, then the remainder vest monthly over the following 36 months, subject to continued service.
- F2: Each RSU equals a contingent right to receive one share of common stock when vested.
- F3: The RSUs vest over four years: 25% on Feb 26, 2027, then equal annual installments over the next three years; RSUs have no expiration date.

Context

These awards are grants of non‑cash compensation to an executive and do not represent immediate marketable shares. The derivative award appears to be stock options (rights to acquire shares upon exercise) while RSUs convert to actual shares only after vesting. Such grants are standard for employee compensation and do not alone indicate buying or selling intent.

Form 4

Period: 2026-02-26

Chief Scientific Officer

Transactions

Award
Stock Options (option to buy)
[F1]
2026-02-26+222,670→ 222,670 total
Exercise: $4.46Exp: 2036-02-26→ Common Stock, par value $0.0001 (222,670 underlying)
Award
Restricted Stock Units
[F2][F3]
2026-02-26+95,430→ 95,430 total
→ Common Stock, par value $0.0001 (95,430 underlying)

Footnotes (3)

[F1]The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on February 26, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
[F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
[F3]The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

Signature

/s/ Gregory Weaver, as Attorney-in-Fact|2026-02-27

1 file